Finance

Lists
Why is 4519 down 2,11%?
Dive Deeper
4519:TYO
Chugai Pharmaceutical Co Ltd
6 040,00 JP¥
-2,11%
(-130,00) 1D
14 қаз., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4519...
Open
6 100 JP¥
High
6 106 JP¥
Low
6 036 JP¥
Mkt. cap
10,14 трлн
Avg. vol.
3,02 млн
Volume
2,36 млн
Dividend
2,28%
Quarterly dividend
34 JP¥
Ex-dividend date
2026 ж. 29 мау.
P/E ratio
21,09
52-wk high
10 700 JP¥
52-wk low
5 974 JP¥
EPS
286 JP¥
Shares outstanding
547,19 млн
No. of employees
5 мың
Open
6 100 JP¥
High
6 106 JP¥
Low
6 036 JP¥
Mkt. cap
10,14 трлн
Avg. vol.
3,02 млн
Volume
2,36 млн
Dividend
2,28%
Quarterly dividend
34 JP¥
Ex-dividend date
2026 ж. 29 мау.
P/E ratio
21,09
52-wk high
10 700 JP¥
52-wk low
5 974 JP¥
EPS
286 JP¥
Shares outstanding
547,19 млн
No. of employees
5 мың
News stories
From web sources and news partners
Profile
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. Wikipedia
About Chugai Pharmaceutical Co Ltd
CEOOsamu Okuda
Employees5,1 мың
Founded1925 ж. 10 нау.
Headquarters-
SectorPharmaceutical industry
Next call 13 күннен кейін
27 қаз., сс, 11:00
Fiscal period
Q3 2026
- / -
Revenue / Est. (JPY)
- / 348,57 млрд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
333,18 млрд
346,30 млрд
321,75 млрд
341,58 млрд
Cost of goods sold
100,24 млрд
87,56 млрд
92,79 млрд
104,22 млрд
Cost of revenue
100,24 млрд
87,56 млрд
92,79 млрд
104,22 млрд
Research and development expenses
48,60 млрд
52,41 млрд
41,89 млрд
47,76 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,89 млрд
36,92 млрд
28,90 млрд
29,04 млрд
Operating expense
76,45 млрд
89,74 млрд
70,19 млрд
76,51 млрд
Total operating expenses
176,69 млрд
177,30 млрд
162,98 млрд
180,73 млрд
Operating income
156,48 млрд
169,01 млрд
158,76 млрд
160,86 млрд
Other non operating income
-356,00 млн
994,00 млн
1,43 млрд
3,04 млрд
EBT including unusual items
156,07 млрд
169,90 млрд
160,20 млрд
169,02 млрд
EBT excluding unusual items
156,07 млрд
169,90 млрд
160,20 млрд
169,02 млрд
Income tax expense
44,86 млрд
41,50 млрд
44,78 млрд
52,69 млрд
Effective tax rate
28,74%
24,42%
27,95%
31,17%
Other operating expenses
-38,00 млн
405,00 млн
-596,00 млн
-291,00 млн
Net income
111,21 млрд
128,41 млрд
115,42 млрд
116,33 млрд
Net profit margin
33,38%
37,08%
35,87%
34,06%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
5,13 млрд
Interest expense
-58,00 млн
-95,00 млн
-
-
Net interest expenses
-58,00 млн
-95,00 млн
-
5,13 млрд
Depreciation and amortization charges
-
-
-
-
EBITDA
156,78 млрд
200,44 млрд
159,26 млрд
161,56 млрд
Gain or loss from assets sale
-
4,53 млрд
-
-
AI content may include mistakes. Learn more
Google қолданбалары